DXVX

• Oral obesity drug with world-first mechanism of action unveiled, drawing strong on-site interest
• Following successful Phase 1 clinical results, global discussions on OVM-200 expand
• Meetings with over 40 companies, including major pharmaceutical companies, out-licensing now within reach

SEOUL, South Korea, July 6, 2026 /PRNewswire/ -- Dx&Vx has successfully expanded its global partnering initiatives at the BIO International Convention 2026 (BIO USA), raising the visibility of its overseas out-licensing opportunities.

Dx&Vx (DXVX, KOSDAQ: 180400), a specialized medical diagnostics and drug development company, announced on July 1st that the company conducted partnering meetings with over 40 global pharmaceutical and biotechnology companies at BIO USA, which took place in San Diego from June 22-25.

BIO USA is the world's largest biotechnology business event, drawing more than 20,000 participants from pharmaceutical companies and investment institutions worldwide, and serves as the premier partnering event for active discussions on technology transfer, joint development, and strategic investment.

During a 13-minute corporate presentation session, the company featured its key pipelines, drawing strong responses from participants. Kevin Kwon, CEO of Dx&Vx, delivered the presentation, introducing the company's anti-cancer drug candidate (OVM-200), oral obesity drug candidate, and nucleic acid/LNP stabilization platform (KRNA), as well as two pipelines from its subsidiary Avixgen: a dry eye disease (DED) treatment candidate (AVI-4015) and a blood–brain barrier penetration platform (ACP).

OVM-200 drew especially strong interest from global partners at this event, building on the successful Phase 1 results that UK-based associate, Oxford VacMedix (OVM) presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in May. Follow-up discussions expanded rapidly as a result.

The company's oral obesity drug candidate, introduced as "the world's first irreversible GLP-1 receptor agonist," also drew considerable attention. This mechanism is currently being developed by Dx&Vx alone worldwide, and its differentiated efficacy attracted strong interest, leading to multiple follow-up partnering meetings.

Kwon said, "The results of our meetings with over 40 companies, including major pharmaceutical companies, are quite promising" and "As our overseas out-licensing outcomes take shape, the company will maintain focus and momentum through to signing."

View original content to download multimedia:https://www.prnewswire.com/news-releases/dxvx-dxvx-partners-with-over-40-global-companies-at-bio-usa-focused-discussions-on-overseas-out-licensing-deals-302818156.html

SOURCE Dx&Vx

• Joint research achievement by Gemelli Hospital in Rome, COREE, COREE Pohang, and the Università Cattolica del Sacro Cuore

SEOUL, South Korea, Sept. 26, 2025 /PRNewswire/ -- COREE announced on September 15 that it had, for the first time in the world, identified microbiome biomarkers specific to diabetes and obesity patients, in collaboration with Italian research teams. The company is led by Chairman Chong-Yoon Lim, who is also the largest shareholder of Dx&Vx.

The announcement was made at the 38th Annual Workshop of the European Helicobacter & Microbiota Study Group (EHMSG), held in Rome, Italy, from September 11 to 13. EHMSG, a prestigious academic platform with over 30 years of history, is an international venue where the latest findings in Helicobacter pylori and microbiome research are presented each year. This year's workshop brought together more than 500 researchers and clinicians from around the world.

COREE participated as an official sponsor of the event, with Chairman Chong-Yoon Lim, CEO Sung-Jun Han, Professor Dae-Hee Kang of Seoul National University, Professor In-Taek Lim of the Catholic University of Korea, and about 30 other Korean scientists in attendance as part of the Future Medical Innovation Forum.

At the workshop, Professor Lorenza Putignani of Sapienza University of Rome and Gemelli Hospital presented the results of a clinical study jointly conducted by Gemelli Hospital, COREE, COREE Pohang, and the Università Cattolica del Sacro Cuore. The study analyzed clinical samples from 93 patients with obesity or type 2 diabetes and 45 healthy controls, successfully identifying for the first time worldwide microbiome distribution patterns unique to these patients.

The research involved metagenomic analysis of stool and saliva samples. Findings showed that the gut microbiome diversity of obese patients was significantly reduced compared to healthy controls. Specific bacterial groups such as Clostridium sp. Q and "CAG-74" were highlighted as potential biomarkers capable of distinguishing patient groups. In type 2 diabetes patients, differences in oral microbiome distribution were observed, with Parvimonas and Aggregatibacter identified as potential biomarkers.

COREE explained that the study is not just a scientific discovery but also a critical foundation for future diagnostic platforms, new drug development, and fecal microbiota transplantation (FMT).

Sung-Jun Han, CEO of COREE, stated, "This is the first time globally that statistically significant microbiome characteristics specific to diabetes and obesity patients have been identified. With further research, these biomarkers could be developed for early diagnosis and prediction of treatment response."

The company emphasized that this achievement provides a clear roadmap for its future growth areas in diagnostics, therapeutics, and FMT solutions.

The academic exchange extended beyond diabetes and obesity research, highlighting broader public health challenges shared by both Italy and Korea. Both countries face extremely low birth rates and rapidly aging populations, making child and senior health critical national priorities.

Dr. In-Taek Lim, former Assistant Minister for Health of the Korea Ministry of Health and Welfare, and now Research Professor at the Catholic University of korea, Graduate School of Public Health and Healthcare Management, commented:

"Both Korea and Italy are confronted with structural challenges of low fertility and rapid aging. This joint research marks an important starting point for future academic and industrial collaborations aimed at tackling common health issues across generations, particularly children and the elderly."

Building on this study, COREE and Gemelli Hospital underscored the importance of expanded research into pediatric and adolescent microbiome health as well as preventive strategies for age-related diseases. Future directions will include initiatives to strengthen maternal and child health as part of efforts to overcome declining birth rates, along with the development of tailored preventive medicine strategies for the elderly.

Professor Dae-Hee Kang of Seoul National University's Department of Preventive Medicine added:

"This achievement serves as a source of great inspiration not only to Korean scientists but also to the global research community. It demonstrates the potential of Helicobacter and microbiome research to evolve into a new therapeutic paradigm."

View original content:https://www.prnewswire.com/news-releases/coree-announces-discovery-of-microbiome-biomarkers-specific-to-diabetes-and-obesity-patients-302568106.html

SOURCE Dx&Vx